Observed responses in research settings are generally mild and may include temporary administration-site irritation, redness, warmth sensations, local sensitivity, temporary itching, mild fatigue, or response variability depending on research amount, administration frequency, protocol duration, and individual sensitivity
Want your GHK-Cu dose, route and cycle set correctly the first time
Youll likely feel more pep in your step, keeping you zooming through the day without the usual afternoon crash
Revised: Mar 2025 Side Effects for Egrifta WR The following important adverse reactions are also described elsewhere in the labeling: Increased risk of neoplasms [see WARNINGS AND PRECAUTIONS ] Elevated IGF-1 levels [see WARNINGS AND PRECAUTIONS ] Fluid retention [see WARNINGS AND PRECAUTIONS ] Glucose intolerance or diabetes mellitus [see WARNINGS AND PRECAUTIONS ] Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS ] Injection site reactions [see WARNINGS AND PRECAUTIONS ] Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice
These symptoms usually resolve as the body adjusts to the peptide sequence
